Severe midtrimester oligohydramnios: treatment strategies

Curr Opin Obstet Gynecol. 2014 Apr;26(2):67-76. doi: 10.1097/GCO.0000000000000051.

Abstract

Purpose of review: Nearly 1% of pregnancies are affected by some type of midtrimester oligohydramnios. Evidence is currently accumulating that suggests the better efficacy of the new therapeutic procedures relative to conventional management. This review summarizes the available evidence.

Recent findings: The prolongation of the period between the diagnosis of oligohydramnios and delivery following amnioinfusion and amniopatch techniques appears to be strongly associated with the gestational age and whether the situation was based on rupture of the membranes or not. Case series reveal that amnioinfusion significantly improves the perinatal outcome and prolongs the pregnancy in severe second-trimester oligohydramnios in both idiopathic cases and those involving rupture of the amniotic membranes [preterm prelabor rupture of the membranes (PPROM)]. There is clear evidence of a lower frequency of perinatal complications and successfully prolonged gestation in iatrogenic PPROM after the amniopatch technique relative to population controls.

Summary: Identification of potentially modifiable risk factors for the successful prolongation of pregnancy complicated with midtrimester oligohydramnios, and previable PPROM is needed for the improvement of treatment strategies and prognosis. Randomized trials are needed to determine whether amniotic fluid-replenishing strategies can improve pregnancy outcomes.

Publication types

  • Review

MeSH terms

  • Amnion / pathology*
  • Amniotic Fluid*
  • Blood Platelets
  • Directive Counseling
  • Factor VIII / therapeutic use*
  • Female
  • Fetal Membranes, Premature Rupture / mortality
  • Fetal Membranes, Premature Rupture / therapy*
  • Fibrinogen / therapeutic use*
  • Gestational Age
  • Humans
  • Infusions, Parenteral
  • Oligohydramnios / mortality
  • Oligohydramnios / therapy*
  • Parents
  • Pregnancy
  • Pregnancy Outcome
  • Pregnancy Trimester, Second*
  • Prognosis
  • Survival Analysis

Substances

  • cryoprecipitate coagulum
  • Factor VIII
  • Fibrinogen